Denmark’s Commit Biologics Appoints Dr. Thomas L.F. Andresen As CEO

The company, which has raised €21.5 million in seed funding from Novo Holdings, Bioqube Ventures, and Korys, brings Dr. Andresen on board as it prepares to advance into clinical development. He will officially assume the role on March 16, 2026.

Dr. Andresen is a seasoned biotech entrepreneur with over 20 years of experience at the intersection of advanced bioengineering and therapeutic innovation. He has a proven track record of transforming early scientific discoveries into commercially viable technologies and has played a key role in securing significant institutional support for multiple biotechnology ventures across Europe and the United States.

Read Also - Pernod Ricard Joins World Travel & Tourism Council As Industry Partner

Commit Biologics is advancing a novel class of therapies through its proprietary Bispecific Complement Engager (BiCE™) platform. The technology leverages the complement system, a potent yet underexplored component of the innate immune response, to selectively eliminate diseased cells offering a promising new modality in immunotherapy.

The company’s confidence is reinforced by positive proof-of-concept results from a non-human primate study reported in late 2025. The study demonstrated rapid deep and durable B-cell depletion without systemic cytokine release providing strong validation of the BiCE™ platform’s efficacy and favorable safety profile ahead of human clinical trials.

With its validated BiCE™ platform Commit Biologics is set to nominate its first two clinical development candidates later in 2026 targeting key unmet medical needs in autoimmune disease and oncology. These selections will mark a major milestone as the company advances toward clinical evaluation.

The broader pipeline strategy focuses on indications where the BiCE™ platform’s unique mechanism of action offers clear advantages including patient populations with compromised T-cell function where conventional immunotherapies may be less effective. This approach aims to unlock novel high-value treatment opportunities for challenging diseases.

In his first remarks as CEO Dr. Thomas Andresen expressed confidence in the company’s science describing complement-powered immune engagers as the next frontier in immunotherapy. He acknowledged the contributions of Interim CEO and CSO Mikkel Wandahl Pedersen for building strong momentum and emphasized his eagerness to work with the team to deliver life-changing therapies for patients.

The appointment of Dr. Thomas Andresen represents a pivotal milestone for Commit Biologics bringing experienced leadership to guide the company’s groundbreaking science. Supported by substantial seed funding and strong preclinical results Commit is well positioned to transition into a clinical tage biotech. As the company prepares to announce its first clinical candidates the biotechnology community will be closely watching its efforts to harness the complement system and redefine the future of immunotherapy.

Anker Lundemose, Chairman of the Board at Commit Biologics, highlighted Dr. Andresen's unique qualifications for the role. He noted that the new CEO's blend of deep scientific knowledge and proven entrepreneurial leadership is ideal for guiding Commit's next growth phase. This appointment is seen as a crucial step in solidifying the company's position as an innovator in complement-targeting therapies.